Top Pharma Appointments of 2024: Leaders Who Are Shaping The Industry

The pharmaceutical world has been buzzing with fresh faces and exciting new appointments in 2024. These leaders are not just here to fill seats — but they are here to bring new energy, bold ideas, and the kind of vision that’s now started to shake things up! From making far-reaching changes in treatments to steering companies toward avant-garde innovations, these pioneers have been making waves in the pharmaceutical industry. 

Do you want a quick rundown of who led the charge and shaped the future of pharma this year? Let’s dive into the top pharma appointments of 2024 and celebrate the leaders who’ve paved the way!

AbbVie Appoints Robert A. Michael as Chief Executive Officer

AbbVie announced that Robert A. Michael, currently president and COO, will succeed Richard A. Gonzalez as CEO on July 1, 2024. Gonzalez, CEO since AbbVie’s founding in 2013, will retire and become executive chairman. Michael, a key driver behind AbbVie’s growth and major acquisitions, has earned the board’s confidence to lead the company forward. The board also praised Gonzalez for his leadership, which has resulted in significant shareholder returns and global expansion.

NS Pharma Appoints Yukiteru Sugiyama As The New President To Lead Next Steps In Orphan Drug Development

NS Pharma has appointed Yukiteru Sugiyama, Ph.D., as its new President, effective June 30, 2024, replacing retiring president Tsugio Tanaka. Sugiyama brings 28 years of experience at Nippon Shinyaku, having worked in research, clinical development, and commercial functions. He will lead the company through subsequent clinical and commercial development phases for treatments like VILTEPSO® (viltolarsen) and CAP-1002 for Duchenne muscular dystrophy, along with other ongoing therapies.

Immunic Names Jason Tardio As The New COO And President

Immunic, Inc. has appointed Jason Tardio as Chief Operating Officer and President, effective July 12, 2024. Tardio will oversee preparations for the potential vidofludimus calcium (IMU-838) launch and collaborate on partnership opportunities. With extensive experience at Novartis and Biogen, he brings valuable expertise in MS drug commercialisation. CEO Daniel Vitt emphasised Tardio’s role in advancing Immunic’s clinical trials. Tardio expressed excitement about the potential of vidofludimus calcium to offer a groundbreaking treatment for MS patients. Additionally, Werner Gladdines has been promoted to Chief Development Officer to expand his leadership in clinical operations.

Lupin Names Industry Veteran Abdelaziz Toumi As CEO Of New API CDMO Subsidiary

Lupin Limited has appointed Abdelaziz Toumi as the CEO of its newly formed subsidiary, Lupin Manufacturing Solutions (LMS), which focuses on developing, producing, and selling active pharmaceutical ingredients (APIs) and expanding its contract development and manufacturing operations (CDMO) business. With over 20 years of experience in the biotech, pharma, and CDMO industries, Toumi has previously held leadership roles at Bayer, Merck, Catalent, and others. Nilesh Gupta, Managing Director of Lupin, expressed excitement about Toumi’s appointment, highlighting his expertise in the API CDMO sector and his role in driving LMS’s global success.

Takeda Names Vatro Mateljic To Lead Canadian Operations

Takeda Canada has appointed Vatroslav (Vatro) Mateljic as its new General Manager to oversee its Canadian operations. With over 25 years of pharmaceutical industry experience, Mateljic served as General Manager for Takeda in Sweden. Ricardo Marek, President of Takeda’s Europe and Canada Business Unit, expressed confidence in Mateljic’s leadership, emphasising his ability to drive business growth and improve patient outcomes. 

Biotech Veteran Dr. Lutz Hilbrich Joins HALIX As CEO To Lead Expansion In Biopharmaceutical Manufacturing

HALIX B.V., a leading contract development and manufacturing organisation, has appointed Dr. Lutz Hilbrich as its new CEO. With over 20 years of experience in biotechnology and pharmaceuticals, Dr. Hilbrich succeeds Alex Huybens, who helped HALIX become a key player in biopharmaceuticals. Dr Hilbrich, with a background in biosimilars, cell and gene therapy, and vaccine development, is eager to build on HALIX's success and continue its innovative work. HALIX, known for its state-of-the-art facilities, has been instrumental in global healthcare, including partnering with AstraZeneca for COVID-19 vaccine production. The company is now poised for further growth under Dr. Hilbrich’s leadership.

Former Vanguard CEO Tim Buckley Joins Pfizer Board, Strengthening Governance and Audit Committees

Pfizer has appointed Tim Buckley to its Board of Directors. Buckley, former chairman and CEO of Vanguard, brings extensive experience in global investment management. He will also join Pfizer's Governance and Sustainability and Audit Committees. Buckley expressed excitement about supporting Pfizer’s mission to innovate and improve health while creating long-term shareholder value. Pfizer CEO Albert Bourla welcomed Buckley, noting his expertise will be a valuable asset to the company.

Nick Galli Joins Alphina Therapeutics As CEO, Strengthens Leadership In Tumor Treatment

Alphina Therapeutics, a biotech company focused on developing an advanced NAMPT inhibitor to treat solid tumours, has appointed Nick Galli as its new CEO and board member. With nearly 20 years of experience in the pharmaceutical and biotech sectors, Galli has helped raise over $450 million in capital. Barbara S. Fox, interim CEO, will now serve as board chair. Alphina is advancing its NAMPT inhibitor program using a synthetic lethality strategy to enhance treatment efficacy and reduce toxicities. The company has also developed a proprietary assay to identify patients most likely to benefit from its treatments. Galli expressed excitement about the company’s potential to improve patient outcomes with solid tumours.

Parexel Appoints Keri Mattox to Chief Business Officer: A New Era of Leadership Begins

Parexel, a leading global clinical research organisation, appointed Keri Mattox as its first Chief Business Officer. With over 25 years of experience in healthcare, Mattox will oversee Parexel’s business operations and growth strategies. She previously held senior roles at companies like Zimmer Biomet, W2O Group, and AmerisourceBergen. Mattox is excited to join Parexel at a pivotal time to help expand the company’s global reach and drive growth. CEO Peyton Howell expressed confidence in Mattox's leadership, highlighting her expertise in the pharmaceutical and medical technology sectors as key to Parexel's future success.

Wrapping It Up! 

So, there you have it —- 2024 has shaped up to be a year full of game-changers in the pharmaceutical industry! All these leaders who have been appointed are not just calling the shots, but they are equally setting the stage for what's next in the healthcare industry. As they push the boundaries of innovation, we are in for some exciting times ahead! Therefore, it's not wrong to say that the future of pharma is in good hands, and with these leaders at the top, we can't wait to see if they'll take us next! 

And you! Yes, are you looking to stay on top of all things pharma? Head to Pharma Now for the latest articles, insider insights, and all the news! 

And hey, why not take it a step further? Subscribe to our magazine for exclusive updates and a deeper dive into the industry. Don’t miss out — join us today and stay connected with the heart of pharma!